Literature DB >> 7059437

A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.

E J Lee, L K Lee.   

Abstract

1 Until recently, phenotyping the N-acetyltransferase enzyme had been restricted to distinguishing the slow acetylators from the rapid. Further separation of the heterozygous rapid phenotype from the homozygous rapid phenotype has only been possible by detailed pharmacokinetic studies using sulphadimidine and necessitating prolonged plasma sampling. 2 A simple method of deriving the basic pharmacokinetic parameters is presented. In this study of ten healthy volunteers, one urine sample and hourly plasma sampling over only 5 h enabled calculation of the total body (TBC) and metabolic clearances (MC) wih enough accuracy to distinguish the three (slow, intermediate and rapid) acetylator phenotypes. The spread of the distribution for the elimination rate constant was however too wide to enable their clear separation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059437      PMCID: PMC1402120          DOI: 10.1111/j.1365-2125.1982.tb01388.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.

Authors:  J R Mitchell; U P Thorgeirsson; M Black; J A Timbrell; W R Snodgrass; W Z Potter; H R Jollow; H R Keiser
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

2.  Acetylator phenotype and the antihypertensive response to hydralazine.

Authors:  A J Jounela; M Pasanen; M J Mattila
Journal:  Acta Med Scand       Date:  1975-04

3.  Relationship of sulfamethazine disposition kinetics to acetylator phenotype in man. A preliminary study.

Authors:  C J Chapron; M R Blum
Journal:  J Clin Pharmacol       Date:  1976-07       Impact factor: 3.126

4.  Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.

Authors:  S D Nelson; J R Mitchell; J A Timbrell; W R Snodgrass; G B Corcoran
Journal:  Science       Date:  1976-09-03       Impact factor: 47.728

Review 5.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

6.  Acetylator phenotype in patients with breast cancer.

Authors:  L N Bulovskaya; R G Krupkin; T A Bochina; A A Shipkova; M V Pavlova
Journal:  Oncology       Date:  1978       Impact factor: 2.935

7.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

8.  Clinical consequences of polymorphic acetylation of basic drugs.

Authors:  D E Drayer; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

9.  Dose-dependent changes in sulfamethazine kinetics in rapid and slow isoniazid acetylators.

Authors:  W Olson; J Miceli; W Weber
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

10.  Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.

Authors:  G A Ellard; P T Gammon
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

View more
  8 in total

1.  The effect of glucose on acetylation status.

Authors:  D Suhardjono; J Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

2.  Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients.

Authors:  P T Reeves; P Hanrahan; J Edelman; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

4.  A simple test for acetylator phenotype using caffeine.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 5.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 6.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

7.  Debrisoquine oxidation in an Australian population.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

8.  N-acetylation polymorphism of dapsone in a Japanese population.

Authors:  Y Horai; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.